Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498316 · ClinicalTrials.gov registry record · Phase 1
Cord Blood Expansion on Mesenchymal Stem Cells
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT00498316: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00498316 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498316, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if combining cord blood units will be safe and result in the cells "taking" faster in recipients. The cord blood units will have their cell number increased in the lab using cells from a family member or they will be collected from an unrelated healthy donor.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Rituximab
- PROCEDURE Cord Blood Infusion
- OTHER ATG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2007-07-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498316
The ClinicalTrials.gov registry entry for NCT00498316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00498316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498316 about?
NCT00498316 is a clinical study titled "Cord Blood Expansion on Mesenchymal Stem Cells". The goal of this clinical research study is to learn if combining cord blood units will be safe and result in the cells "taking" faster in recipients. The cord blood units will have their cell number increased in the lab using cells from a family member or they will be collected from an unrelated he...
What is the current status of trial NCT00498316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2007-07-03. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00498316?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Rituximab (DRUG), Cord Blood Infusion (PROCEDURE), ATG (OTHER).
Who is sponsoring clinical trial NCT00498316?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.